Search results
Results From The WOW.Com Content Network
Ruxolitinib (sold under the brand names Jakafi and Jakavi among others, and as Opzelura in cream form) is a medication used for the treatment of intermediate or high-risk myelofibrosis, [6] a type of myeloproliferative neoplasm that affects the bone marrow; [11] [12] polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; [6] [13] and steroid-refractory ...
Deuruxolitinib, sold under the brand name Leqselvi, is a medication used for the treatment of alopecia areata. [1] It is a Janus kinase inhibitor selective for JAK1 and JAK2. [2]
Baricitinib is a Janus kinase (JAK) inhibitor that reversibly inhibits Janus kinase 1 with a half maximal inhibitory concentration (IC 50) of 5.9 nM and Janus kinase 2 with an IC 50 of 5.7 nM. Tyrosine kinase 2 , which belongs to the same enzyme family, is affected less (IC 50 = 53 nM), and Janus kinase 3 far less (IC 50 > 400 nM).
The authorisation procedure is one of the regulatory tools of the European regulation (EC) REACH n°1907/2006 aiming to ban the use of substances of very high concern included in the Annex XIV of REACH, so as to replace them with technically and economically feasible alternatives.
Nilotinib is used to treat Philadelphia chromosome (Ph+)-positive chronic myelogenous leukaemia. [3] [6] It is indicated for the treatment of newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase; [3] [5] adults with chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia resistant to or intolerant to prior therapy that ...
The petition filed by over 20 consumer advocacy groups in 2022 that argued for the removal of Red Dye No. 3 from food and dietary supplements cited studies, the FDA's prior use of the Delaney ...
Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. . It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinas
U.S. Treasury nominee Scott Bessent on Thursday faced sharp questions from both Democrats and Republicans on tax policy, tariffs, China, Russia sanctions and the future of an IRS tax filing system ...